| Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral, urinary and respiratory infections. Meridian diagnostic products are used out... More >> |
| | | Date | Title | | | 06/10/09 | Meridian Bioscience to Present at the William Blair and Company's 29th Annual Growth Stock Conference| CINCINNATI--(BUSINESS WIRE)--Jun. 10, 2009--
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that the
Company has been invited to present at the William Blair and Company’s 29th
Annual Growth Stock Conference on Thursday, June 11 at 9:20 a.m. CDT at
the Four Seasons Hotel, Chicago, IL. Jack Kraeutler, Chief Executive
Officer, and Bill Motto, Executive Chairman of the Board, are scheduled
to present. A question and answer session will f... |
|  | | 06/04/09 | Meridian Bioscience Wins GHX 2009 Best in Class Award| CINCINNATI--(BUSINESS WIRE)--Jun. 4, 2009--
Meridian Bioscience (NASDAQ: VIVO) today announced that it is a
recipient of a 2009 GHX Best in Class Award for achieving the highest
year-over-year market share growth for distributed products in the
Microbiology Reagents/Supplies product category for the 2008 calendar
year.
Meridian Bioscience was among the 30 leading medical-surgical product
manufacturers recognized by GHX in five market... |
| | | 06/03/09 | Meridian Bioscience Receives FDA Clearance for New Rapid Campylobacter Test| CINCINNATI--(BUSINESS WIRE)--Jun. 3, 2009--
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has
received FDA clearance from the U.S. Food and Drug Administration (FDA)
for a new rapid test for Campylobacter, ImmunoCard STAT!®
CAMPY. This new test provides fast and accurate detection of Campylobacter
bacteria, one of the most common causes of diarrheal illness and the
most common bacterial cause of foodborne illness in the United Stat... |
| | | 04/16/09 | Meridian Bioscience Reports Record Second Quarter and Six Months Operating Results, Declares Regular Cash Dividend, and Revises Downward Fiscal 2009 Guidance| CINCINNATI, Apr 16, 2009 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
reported second quarter and six months net sales of $33.3 million and
$67.6 million, respectively, decreases of 8% and 4% compared to the
same periods of the prior fiscal year;
reported second quarter and six months operating income of $11.0
million and $23.2 m... |
| |
|
| | * Data collected 06/14/09 - 06/21/09 |
|
|
|
| |
